Log in to save to my catalogue

Patient-centred outcomes and effect of disease progression on health status in patients with newly d...

Patient-centred outcomes and effect of disease progression on health status in patients with newly d...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2519268885

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

About this item

Full title

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

Publisher

England: Elsevier Ltd

Journal title

The lancet oncology, 2021-05, Vol.22 (5), p.632-642

Language

English

Formats

Publication information

Publisher

England: Elsevier Ltd

More information

Scope and Contents

Contents

SummaryBackgroundIn the phase 3 SOLO1 trial, maintenance olaparib provided a significant progression-free survival benefit versus placebo in patients with newly diagnosed, advanced ovarian cancer and a BRCA mutation in response after platinum-based chemotherapy. We analysed health-related quality of life (HRQOL) and patient-centred outcomes in SOLO...

Alternative Titles

Full title

Patient-centred outcomes and effect of disease progression on health status in patients with newly diagnosed advanced ovarian cancer and a BRCA mutation receiving maintenance olaparib or placebo (SOLO1): a randomised, phase 3 trial

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_proquest_journals_2519268885

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2519268885

Other Identifiers

ISSN

1470-2045

E-ISSN

1474-5488

DOI

10.1016/S1470-2045(21)00098-X

How to access this item